Immunotropic therapy using Ruzam in treating patients suffering from atopy: edge of success

Maksimova A.V.; Tataurshchikova N.S.

doi:https://doi.org/10.17116/immunology2025101127

Maksimova A.V.

Peoples’ Friendship University of Russia named after Patrice Lumumba

Tataurshchikova N.S.

Peoples’ Friendship University of Russia named after Patrice Lumumba

ORCID: 0000-0002-3486-8188

Immunotropic therapy using Ruzam in treating patients suffering from atopy: edge of success

Authors:

Maksimova A.V., Tataurshchikova N.S.

More about the authors

Journal: Journal of Adaptive Medical Immunology and Public Health Issues. 2025;1(1): 27‑32

DOI: 10.17116/immunology2025101127

Read: 122 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Maksimova AV, Tataurshchikova NS. Immunotropic therapy using Ruzam in treating patients suffering from atopy: edge of success. Journal of Adaptive Medical Immunology and Public Health Issues. 2025;1(1):27‑32. (In Russ.)
https://doi.org/10.17116/immunology2025101127

Использование инфографики авторами научных работ

Close metadata

Abstract:

The search for new safe and effective methods of immunomodulatory treatment that will prevent the exacerbation of the disease, the development of exacerbations and complications remains a priority task of modern allergology and immunology. This article presents current data on the possibilities of nonspecific immunotropic therapy with the drug Ruzam in the treatment of allergic diseases, including in immunocompromised patients. The drug Ruzam performs endogenous regulation of processes aimed at eliminating immunological dysfunction and suppressing allergic inflammation by influencing cellular and humoral immune responses and nonspecific resistance of the body through the regulation of key cytokines, polarizing the immune response from Th2 to Th1 cells, and reducing the level of IgE in the blood. Due to its universal anti-inflammatory effect, the drug Ruzam has established itself as the first-line drug of choice in patients with AD—the number of exacerbations and their severity decreased during the pollination period of causally significant plants, and the total amount of pharmacological assistance required during the pollen season also decreased. The clinical efficacy of the drug Ruzam in patients with asthma has been confirmed: the intensity and severity of asthma attacks decreased, the amount of drug therapy was reduced by half during treatment, and the duration of remission increased to an average of 2—3 years. The efficacy of Ruzam in AR has been confirmed by its positive therapeutic effect on all major symptoms of AR. The clinical efficacy of Ruzam in patients with AD has been confirmed in studies—compared to placebo, Ruzam significantly reduces the SCORAD index (by 58.93%) and the duration of relapses (by 40%) in patients with mild to moderate AD.

Keywords:

Ruzam

allergic diseases

immunocompromised patient

Authors:

Maksimova A.V.

Peoples’ Friendship University of Russia named after Patrice Lumumba

Tataurshchikova N.S.

Peoples’ Friendship University of Russia named after Patrice Lumumba

ORCID: 0000-0002-3486-8188

Received:

14.07.2025

Accepted:

25.08.2025

Close metadata

References:

Tong X, Tong H, Gao L, Deng Y, Xiang R, Cen R, Zhao Y, Wang P, Li G, Shen J, Xu B, He B, Kong Y, Tao Z, Xu Y; Hubei Medical Quality Control Center for Allergic Disease. A Multicenter Study of Prevalence and Risk Factors for Allergic Rhinitis in Primary School Children in 5 Cities of Hubei Province, China. International Archives of Allergy and Immunology. 2022;183(Iss. 1): 34-44. https://doi.org/10.1159/000517948
Maksimova AV, Tatarushchikova NS. Immunocompromised patients: current possibilities of pathogenetic immunotropic therapy. E`ffektivnaya farmakoterapiya. 2024;20(38):72-76. (In Russ.). https://doi.org/10.33978/2307-3586-2024-20-38-72-76
Osipova GL, Terekhova EP , Terekhov DV, Luizo TI. Study of the prophylactic efficacy of the polypeptide drug Ruzam in patients with polyvalent sensitization and seasonal allergic rhinitis in routine practice. Prakticheskaya allergologiya. 2024;1:4-13. (In Russ.). https://doi.org/10.46393/27129667_2024_1_4
Instrukciya po primeneniyu lekarstvennogo preparata dlya medicinskogo primeneniya Ruzam. Accessed August 15, 2025. (In Russ.). https://www.rlsnet.ru/drugs/ruzam-5936?ysclid=meck2i11e7138493393
Goryachkina LA, Marinina IA. Opy`t primeneniya specificheskoj immunoterapii v sochetanii s preparatom RUZAM dlya lecheniya pollinozov i bronxial`noj astmy`. Sbornik «RUZAM — nadezhnaya zashhita ot allergii». M., 2002: 16-20. (In Russ.).
Stezhkina EV, Chuchalin AG, Kolganova NA, Aisanov ZR. Comparative prospective randomized double-blind placebo-controlled study of the antiallergic effect of the drug Ruzam on clinical indicators and markers of allergic inflammation in patients with persistent allergic rhinitis. Nauchny`j zhurnal dlya praktikuyushhix vrachej. 2012;1:12-19. (In Russ.).
Kazakova GA, Vasilieva OS, Dmitrova TP, Chuchalin AG. Respiratory syndrome in latex allergy. Pul`monologiya. 2003;5:71-79. (In Russ.).
Kolgonova NA. Bronxial`naya astma i mul`tisistemny`e proyavleniya atopii. Novy`e terapevticheskie pod xody`. Dis. … dokt. med. nauk. M., 2001. (In Russ.).
Osipova GL. Ruzam in the complex therapy of allergic diseases. RMZh. 2002;10(5):278-281. (In Russ.).
Novikova NV, Maslennikov VV, Reznikov YuP, Kolganova NA. The use of Ruzam to achieve control over atopic bronchial asthma in patients with frequent respiratory infections. Farmateka. 2013;15 (268):30-33. (In Russ.).
Gaichieva ZN. Ocenka e`ffektivnosti, bezopasnosti i otdalenny`x rezul`tatov dejstviya polipeptidnogo preparata «RUZAM» v kompleksnoj terapii pacientov s bronxial`noj astmoj i atopicheskim dermatitom. Dis. … kand. med. nauk. M., 2005. (In Russ.).